Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma

Authors

  • YunMi Qiu Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • Kamran Ali Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • HaiYue Lou Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • JingPeng Shan Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China
  • Liming Wu Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, No.261, Huansha Road, Hangzhou, P. R. China

DOI:

https://doi.org/10.2340/actadv.v101.224

Keywords:

atopic dermatitis, dupilumab, non-Hodgkin’s lymphoma

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377-388.

https://doi.org/10.1016/j.jaad.2019.07.074 DOI: https://doi.org/10.1016/j.jaad.2019.07.074

Chun PIF, Lehman H. Current and future monoclonal antibodies in the treatment of atopic dermatitis. Clin Rev Allergy Immunol 2020; 59: 208-219.

https://doi.org/10.1007/s12016-020-08802-9 DOI: https://doi.org/10.1007/s12016-020-08802-9

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018; 41: 489-509.

https://doi.org/10.1007/s40264-017-0636-9 DOI: https://doi.org/10.1007/s40264-017-0636-9

Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol 2019; 99: 899-900.

https://doi.org/10.2340/00015555-3201 DOI: https://doi.org/10.2340/00015555-3201

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111-1116.

https://doi.org/10.1016/j.jaci.2009.02.028 DOI: https://doi.org/10.1016/j.jaci.2009.02.028

Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf 2021; 20: 997-1004.

https://doi.org/10.1080/14740338.2021.1939673 DOI: https://doi.org/10.1080/14740338.2021.1939673

Miyashiro D, Vivarelli AG, Goncalves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther 2020; 33: e13880.

https://doi.org/10.1111/dth.13880 DOI: https://doi.org/10.1111/dth.13880

Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 2020; 83: 197-199.

https://doi.org/10.1016/j.jaad.2020.03.050 DOI: https://doi.org/10.1016/j.jaad.2020.03.050

Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol 2004; 84: 327-328.

https://doi.org/10.1080/00015550410025967 DOI: https://doi.org/10.1080/00015550410025967

Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol 2020; 156: 1086-1097.

https://doi.org/10.1001/jamadermatol.2020.1948 DOI: https://doi.org/10.1001/jamadermatol.2020.1948

Downloads

Published

2022-01-04

How to Cite

Qiu, Y., Ali, K., Lou, H., Shan, J., & Wu, L. (2022). Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma . Acta Dermato-Venereologica, 102, adv00625. https://doi.org/10.2340/actadv.v101.224

Issue

Vol. 102 (2022)

Section

Short Communication

Categories

License

Copyright (c) 2021 YunMi Qiu, Kamran Ali, HaiYue Lou, JingPeng Shan, Liming Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.